New Delhi: India-made COVID vaccine ‘COVAXIN’ is likely to be launched by February next year, media reports stated citing ICRM officials.
COVAXIN, an inactivated vaccine, is being developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The last stage trials of COVAXIN have started this month and the results so far have shown that it is safe and effective, informed senior ICMR scientist Rajni Kant to the media.
The vaccine has shown good efficacy and it is expected that by the beginning of next year, February or March, he added.
Meanwhile, India’s COVID-19 caseload jumped to 83,64,086 with a spike of 50,554 new infections, informed the Union Health Ministry on Thursday.
This is for the first time in a week that the country had reported over 50,000 cases in a single day.
The total number of active cases in India now stands at 5,27,962 and recovered cases at 77,11,809.
The COVID-19 death toll mounted to 1,24,315 after 704 more patients succumbed to the virus.